INTRODUCTION
The discovery of human pluripotent stem cells (hPSC) opened the possibility of generating replacement cells and tissues in the laboratory that could be used for disease treatment and drug screening. Recent research has moved the stem cell field closer to that goal through development of strategies to generate cells that would otherwise be difficult to obtain, like neurons or cardiomyocytes (Kriks et al., 2011; Shiba et al., 2012; Son et al., 2011) . These cells have also been transplanted into animal models, in some cases with a beneficial effect like suppression of arrhythmias with stem-cell-derived cardiomyocytes (Shiba et al., 2012) , restoration of locomotion after spinal injury with oligodendrocyte progenitors (Keirstead et al., 2005) , or improved vision after transplantation of retinal epithelial cells into rodent models of blindness (Lu et al., 2009) .
One of the rapidly growing diseases that may be treatable by stem-cell-derived tissues is diabetes, affecting >300 million people worldwide, according to the International Diabetes Federation. Type 1 diabetes results from autoimmune destruction of b cells in the pancreatic islet, whereas the more common type 2 diabetes results from peripheral tissue insulin resistance and b cell dysfunction. Diabetic patients, particularly those suffering from type 1 diabetes, could potentially be cured through transplantation of new b cells. Patients transplanted with cadaveric human islets can be made insulin independent for 5 years or longer via this strategy, but this approach is limited because of the scarcity and quality of donor islets (Bellin et al., 2012) . The generation of an unlimited supply of human b cells from stem cells could extend this therapy to millions of new patients and could be an important test case for translating stem cell biology into the clinic. This is because only a single cell type, the b cell, likely needs to be generated, and the mode of delivery is understood: transplantation to a vascularized location within the body with immunoprotection.
Pharmaceutical screening to identify new drugs that improve b cell function, survival, or proliferation is also hindered by limited supplies of islets and high variability due to differential causes of death, donor genetic background, and other factors in their isolation. A consistent, uniform supply of stem-cell-derived b cells would provide a unique and valuable drug discovery platform for diabetes. Additionally, genetically diverse stem-cell-derived b cells could be used for disease modeling in vitro or in vivo.
Studies on pancreatic development in model organisms (Gamer and Wright, 1995; Henry and Melton, 1998; Ninomiya et al., 1999; Apelqvist et al., 1999; Kim et al., 2000; Hebrok et al., 2000; Murtaugh et al., 2003) identified genes and signals important for the pancreatic lineage, and these have been effectively used to form cells in the b cell lineage in vitro from hPSC. Definitive endoderm and subsequent pancreatic progenitors can now be differentiated with high efficiencies (Kroon et al., 2008; D'Amour et al., 2005 D'Amour et al., , 2006 Rezania et al., 2012) . These cells can differentiate into functional b cells within 3-4 months following transplantation into rodents (Kroon et al., 2008; Rezania et al., 2012) , indicating that some cells in the preparation contain the developmental potential to develop into b cells if provided enough time and appropriate cues. Unfortunately, the monthslong process the cells undergo in vivo is not understood, and it is unclear whether this process of in vivo differentiation would also occur in human patients. Attempts to date at generating insulin-producing (INS+) cells from human pancreatic progenitors in vitro have generated cells with immature or abnormal phenotypes. These cells either fail to perform glucose-stimulated insulin secretion in vitro, fail to express appropriate b cell markers such as NKX6-1 or PDX1, abnormally coexpress other hormones like glucagon (GCG), fail to function after transplantation in vivo, or display a combination of these abnormal features (D'Amour et al., 2006; Cheng et al., 2012; Hrvatin et al., 2014; Narayanan et al., 2014; Xie et al., 2013; Nostro et al., 2011) .
Herein, we report the discovery of a strategy for large-scale production of functional human b cells from hPSC in vitro. By using sequential modulation of multiple signaling pathways in a three-dimensional cell culture system, without any transgenes or genetic modification, we generate glucose-responsive, monohormonal insulin-producing cells that show key features of a bona fide b cell, including coexpression of key b cell markers and b cell ultrastructure. Furthermore, these cells mimic the function of human islets both in vitro and in vivo. Finally, we demonstrate the potential utility of these cells for in vivo transplantation therapy for diabetes.
RESULTS
Generation of Glucose-Sensing Insulin-Secreting b Cells In Vitro Our strategy to generate functional b cells from hPSC in vitro is outlined in Figure 1A . To produce large numbers, we used a scalable suspension-based culture system that can generate >10 8 hPSCs and later differentiated cell types (modified from Schulz et al., 2012) . Clusters of cells (100-200 mm in diameter, each cluster containing several hundred cells) from a human embryonic stem cell (hESC) line (HUES8) or two human-induced pluripotent stem cell (hiPSC) lines (hiPSC-1 and hiPSC-2) were induced into definitive endoderm (>95% SOX17+ cells, DE cells in Figure 1A ) and subsequently early pancreatic progenitors (>85% PDX1+ cells, PP1 cells in Figure 1A) .
Transplantation of pancreatic progenitors expressing PDX1+/ NKX6-1+ (PP2 in Figure 1A ) into mice gives rise to functional b cells in vivo after 3-4 months (Kroon et al., 2008; Rezania et al., 2012) . And previous studies had shown that these PDX1+/ NKX6-1+ pancreatic progenitors (PP2) could be further differentiated in vitro into some INS+ cells along with INS+/GCG+ or INS+/SST+ polyhormonal (PH) cells (Nostro et al., 2011; Rezania et al., 2012; Thowfeequ et al., 2007; Aguayo-Mazzucato et al., 2013; D'Amour et al., 2006; Hrvatin et al., 2014) . We use the nomenclature PH (polyhormonal, Figure 1A ) to refer to this cell population of in-vitro-differentiated hPSCs. Transcriptional analysis of in-vitro-differentiated PH cells showed that these cells resemble human fetal and not adult b cells (Hrvatin et al., 2014) . Because these PH cells show neither glucose-stimulated insulin secretion (GSIS) nor other key properties of bona fide b cells, we returned to the earlier pancreatic progenitor step (PP2) to investigate ways to make NKX6-1+/C-peptide+ (EN cells in Figure 1A ) and functional b cells (SC-b cells in Figure 1A ). We first extended the time in culture with the FGF family member KGF, hedgehog inhibitor SANT1, and a low concentration of retinoic acid to generate high levels of NKX6-1+/PDX1+ coexpressing pancreatic progenitor clusters (>55% NKX6-1+/PDX1+ cells, PP2 cells in Figure 1A ). These PP2 cells were the starting point to make differentiated cells that would respond to glucose and mimic natural b cells. Systematic testing of the concentration and exposure time of numerous factors (small-molecule agonists and antagonists and assorted growth factors) on pancreatic progenitors (PP2 cells in Figure 1A ) led to the development of a new differentiation protocol. This protocol takes 4-5 weeks and involves a unique combination of sequential culture steps using factors that affect signaling in numerous pathways, including signaling by wnt, activin, hedgehog, EGF, TGFb, thyroid hormone, and retinoic acid, as well as g-secretase inhibition (see Experimental Procedures) . In all, we tested >150 combinations involving >70 compounds, many of which had been described in the literature as playing a role in pancreatic biology. Most factors and combinations had little appreciable effect on cell function and gene expression, but we were able to develop a protocol using 11 different factors that provided a significant improvement in function and b-cell-like gene expression (Table S1 available online) .
A key functional feature of a b cell is its ability to repeatedly perform GSIS. Nearly all existing directed differentiation protocols generate insulin-expressing cells from hPSC (see PH in Figure 1A) that are defective in GSIS in vitro; these cells fail to respond to even a single glucose challenge. In contrast, the SC-b cells generated from both hESC and hiPSC cells with the new protocol respond to multiple sequential high-glucose challenges and depolarization with KCl ( Figures 1B, S1 , and S2A). This data contrasts with the response of PH cells (Figures 1C) , which secrete very low amounts of insulin and are not glucose responsive. SC-b cell clusters and primary adult (cadaveric) islets show a similar response to sequential glucose challenges (compare Figures 1B and 1D) .
Twelve independent differentiation batches of SC-b cells (eight hESC and four hiPSC) were tested with three sequential high-glucose challenges (three to four replicates of each) and compared to five batches of PH cell clusters and four sets of cadaveric islets ( Figures 1E-1G ). Because the SC-b cells outperformed PH cells, we compared SC-b cell clusters to primary islet cells. The stimulation index, as calculated by the ratio of insulin secreted in high glucose (20 mM) to low glucose (2 mM), was similar for SC-b cells and primary adult islets, 2.2 ± 0.3 and 2.1 ± 0.9, respectively.
Some batch-to-batch and donor-to-donor variation is observed for both primary adult b cells and SC-b cells. This variation is not unexpected for islets from cadavers nor for cells taken through a 35 day protocol involving five basal media and 11 combinatorially added factors ( Figures 1E and 1G ). Some batches of SC-b cells and primary human islets fail to respond to individual glucose challenges (see Figures S1A and S1C ). But overall, SC-b cell clusters and primary islets responded to high glucose challenges at a similar frequency: 75% ± 8% and 72% ± 17%, respectively.
The amount of insulin secreted per cell in response to 20 mM glucose by SC-b cells was similar to that secreted by primary adult b cells, averaging 1.6 ± 0.2 and 3.6 ± 0.7 mIU/10 3 cells, respectively. Notably, some SC-b cell batches secreted as much insulin as cadaveric islets (see Figures 1E and 1G ). Total insulin content per cell was 240 ± 50 mIU/10 3 cell for SC-b clusters (two batches) and 200 ± 40 mIU/10 3 for primary islets (one batch). The proinsulin-to-insulin ratio was 0.030 ± 0.001 and 0.029 ± 0.006 for SC-b and primary adult b cells, respectively. Taken together, these data highlight the difference between SC-b and PH cell clusters and suggest that the in vitro function of SC-b cells is similar to their bona fide adult b cell counterparts.
Calcium Flux in SC-b Cells
We sought to further confirm the in vitro function of SC-b cells by measuring changes in intracellular Ca
2+
. b cells sense changing glucose levels through calcium signaling; increasing glucose levels leads to membrane depolarization, causing an influx of calcium ions, which triggers insulin exocytosis (Mohammed et al., 2009) . Calcium influx depends on glucose transport and metabolic enzymes as well as functioning potassium ion channels (Rutter and Hodson, 2013) . We monitored calcium influx in cell clusters stained with Fluo-4 AM, a cell-permeable fluorescent calcium indicator dye, in real time, using fluorescent microscopy ( Figure 2A ). This method allowed us to analyze calcium flux at both the population and single-cell level. The population analysis shows that cells in both SC-b cell clusters and primary adult islets respond to sequential glucose challenges by repeatedly increasing intracellular Ca 2+ in a similar manner, consistent with normal glucose responsiveness. In contrast, PH cell clusters displayed an abnormal calcium response ( Figure 2B ). Single-cell analysis reveals that most individual cells in SC-b cell clusters and primary adult islets respond to two to three sequential glucose challenges by fluxing calcium, whereas most cells from PH cell clusters do not ( Figures 2C-2E ). These data show that both the entire population as well as individual cells within the SC-b cell clusters flux calcium similarly to primary human islet cells and further support the conclusion that these SC-b cells function in vitro.
Stem-Cell-Derived b Cells Resemble Primary Human b Cells
The results in Figures 1 and 2 show that SC-b cells display the physiological function in vitro of secreting insulin in response to glucose. We next analyzed protein expression, RNA expression, and ultrastructure of SC-b cells. As with many previously reported hPSC-derived insulin-producing cells, our PH protocol C-peptide+ cells fail to coexpress the b cell transcription factor NKX6-1. Conversely, SC-b cells, like islet b cells, stained positive for cytoplasmic C-peptide and the nuclear protein NKX6-1 (Figures 3A and S2B) . SC-b cells stain positive for both insulin and C-peptide, a stoichiometric byproduct of proinsulin processing, indicating that the insulin produced comes from cell-endogenous insulin synthesis (data not shown). Nuclear expression of the transcription factor PDX1 is characteristic of human b cells, and most PH cells do not coexpress PDX1 in C-peptide+ cells ( Figure 3B ). Both cadaveric islet b cells and SC-b cells coexpress this key protein in C-peptide+ cells ( Figures 3B and S2C ).
Others have noted previously (Bruin et al., 2014; Hrvatin et al., 2014 ) that most protocols for pancreatic differentiation generate many cells that coexpress glucagon and insulin/Cpeptide+, and we observed polyhormonal cells in the control PH differentiations. In contrast, the majority of C-peptide+ cells in SC-b differentiations are monohormonal by IHC (Figures 3C and S2D) and by flow cytometry ( Figure S3 ). We also observed a minor population of monohormonal SST+ d cells and GCG+ a cells ( Figures 3C, S2D , and S3). There are also a few polyhormonal cells-on average, 7.7% ± 0.7% of C-peptide+ cells coexpress glucagon and 4.7% ± 0.1% coexpress somatostatin ( Figure S3 ).
The most parsimonious explanation is that the SC-b cells can be found within the NKX6-1+/C-peptide+ monohormonal population. Flow cytometry reveals that the new protocol produces an average of 33% ± 2% (n = 12) NKX6-1+/C-peptide+ cells, similar to the 26% ± 3% (n = 3) average observed in cadaveric islets 
SC-b Cell Ultrastructure
In light of the observation that SC-b cells secrete insulin in a physiological manner in vitro, we hypothesized that SC-b cells might also package insulin protein into secretory granules, as do primary b cells. b cells package insulin into secretory granules that initially appear as pale gray cores surrounded by a small electron-lucent area or light halo, and these condense into granules with dark polygonal crystalline cores surrounded by a light halo (Deconinck et al., 1971; Like and Orci, 1972) . Previous studies of INS+ cells showed abnormal granules that resemble a-like granules with round cores surrounded by a dark gray halo (PH cells; D'Amour et al., 2006; Deconinck et al., 1971; Like and Orci, 1972) and/or abnormal granules of indistinct hormonal character. We recapitulated these results with our control protocol, producing INS+ cells that had abnormal and a-like granules and few, if any, b cell granules ( Figures 4A and 4B ). In contrast, our new differentiation strategy generates SC-b cells that package and crystallize insulin protein into granules that are structurally similar to primary b cell insulin granules. Both developing insulin granules and mature, crystallized insulin granules are observed in SC-b cells and primary human b cells. SC-b cells and primary b cells averaged 66 ± 11 and 77 ± 8 insulin granules per cell, respectively ( Figure 4C ). Immunogold labeling with particles against insulin and glucagon showed that granules in the PH cells contained both insulin and glucagon protein, whereas primary human b cell and SC-b cell granules contained only insulin ( Figure 4D Tables S2 and S3 ). When primary human islets (500 ieq, or islet equivalents) are transplanted, human insulin is detected in the serum of glucose-challenged mice within 2 weeks ( Figure 5A ). Conversely, when 5 million pancreatic progenitor cells are transplanted into mice, no insulin is detected at 2 weeks posttransplant (data not shown) (Kroon et al., 2008; Schulz et al., 2012; Rezania et al., 2012) . A portion of the cells in this pancreatic progenitor population will differentiate further and secrete insulin, but only after a 3-4 month long ill-understood maturation phase in vivo.
We tested whether insulin is detectable in serum of animals transplanted with 5 million SC-b cells sooner than 3-4 months. After a brief surgical recovery period (2 weeks), mice transplanted with SC-b cells were injected with glucose and serum was collected 30 min later. ELISA measurement of human insulin in the serum revealed that SC-b cells from both hESC and hiPSC secrete insulin into the host bloodstream within 2 weeks, the earliest posttransplantation time point tested ( Figure 5A) . As a control, we also transplanted the same number of PH cells and pancreatic progenitors, neither of which secreted significant levels of insulin in vivo within 2 weeks, as has been previously published (Kroon et al., 2008 ) (data not shown and Figure 5A ). To test whether the SC-b cells secrete insulin in response to glucose, we measured human insulin in the bloodstream of a subset of mice both before (0 min) and after (30 min) an acute glucose challenge. 73% of SC-b-cell-transplanted mice (27/37 animals) showed increased human insulin in the bloodstream after a glucose challenge, 2 weeks posttransplant ( Figure 5A and Tables S2 and S3 ). By comparison, 75% of mice transplanted with human islets (9 out of 12 animals) showed increased human insulin secretion after the glucose challenge. This increase in human insulin with transplanted SC-b cells is statistically significant (p = 0.0008). As another measure of in vivo GSIS, the average ratio of insulin secreted after the glucose challenge compared to before it was 1.9 ± 0.3 for islet transplants and 1.7 ± 0.2 for SC-b cell transplants. These in vivo stimulation indices ranged from 0.4 to 4.3 for islet transplants and from 0.5 to 3.8 for SC-b cell transplants (Tables S2 and S3) .
After 2 weeks posttransplantation, animals were sacrificed and the engrafted kidneys were removed for histology. IHC showed that both SC-b cell and human islet grafts contain C-peptide+ cells adjacent to the mouse kidney ( Figures 5B and S5) . Analysis of C-peptide and glucagon staining further revealed that the SCb cells remained monohormonal after transplantation (Figures 5B and S5) . A minor population of GCG+ cells, which was observed before transplantation ( Figures 3C, S2D , and S3), was also observed in the grafts (Figures 5B and S5 ).
Utility of Stem-Cell-Derived b Cells for Treating Diabetes
A major challenge for the stem cell field has been to generate differentiated cells that mimic their normal, in vivo counterparts. We examined how useful SC-b cells would be as a cell therapy in a diabetic animal model. One useful diabetes model is the Akita mouse (Yoshioka et al., 1997) , which has a mutation in the insulin gene, leading to protein misfolding, irreversible b cell failure, and progressively severe hyperglycemia. Immunodeficient NODRag1 null IL2rg null Ins2 Akita (NRG-Akita) mice can be restored to normoglycemia via mouse or human islet transplantation (Brehm et al., 2010) . We tested whether SC-b cells could also function to control diabetic hyperglycemia. Transplantation of SC-b cells, but not PH cells, into the kidney capsule of NRG-Akita mice rapidly reversed the progressively worsening hyperglycemia observed in these animals ( Figure 6A ). Fasting blood glucose measurements of mice transplanted with SC-b cells averaged <200 mg/dl, whereas those transplanted with control PH cells showed progressively higher blood glucose levels that approached 600 mg/dl, as has been observed for nontransplanted NRG-Akita mice ( Figure 6A ) (Brehm et al., 2010) . Mice that received SC-b cells also rapidly cleared glucose from the blood Figures S2B, S2C, S3 , and S4. CP, C-peptide; SST, somatostatin; GCG, glucagon. Scale bar = 100 mm. after a glucose injection, similar to the glucose clearance found in a separate independent cohort of NRG-Akita mice transplanted with 4000 IEQ of human islets (Figures 6B). We measured human insulin in the bloodstream 18 weeks after transplantation and found mice that received SC-b cells maintained human insulin secretion ( Figure 6C ).
Mice transplanted with SC-b cells also survived better than control mice: two out of six mice that received PH cells died 
DISCUSSION
Here, we show that functional human SC-b cells can be directly generated from human pluripotent stem cells in vitro. The data presented demonstrate that these cells function similarly to primary human b cells both in vitro and in vivo posttransplantation. These cells can be generated without genetic modification and in large numbers (billions of cells). Though not all of the cells present at the end of the protocol are SC-b cells, the percentage of NKX6-1+/C-peptide+ cells in the clusters is similar to that found in human islets, and the size of the clusters is comparable, though slightly larger on average than human islets (200-250 mm diameter versus 100-150 mm diameter). This is all accomplished ex vivo by the addition of defined factors, without the addition of mesenchymal or endothelial cells that normally accompany b cell development. All images were taken with a Olympus IX51 microscope. See also Figure S5 and Tables S2 and  S3 . Scale bar, 100 mm.
Although we observed that the global gene expression patterns of SC-b cells are more similar to adult human b cells than to fetal b cells, or previously produced INS+ cells, gene expression differences still remain. One possibility is that additional modifications to the culture media or added factors could shift the cells even closer to primary b cells. Another possibility is that gene expression patterns in cadaveric b cells result from varied causes of death of the donors, the isolation and recovery process, or shipping or arise from the influence of adjacent nonendocrine cells. Future studies will include a more detailed analysis of the gene expression differences between SC-b and primary b cells. Two differentiated b cell markers, UCN3 (Blum et al., 2012) and MAFA (Aguayo-Mazzucato et al., 2013) , were not investigated because of the low sensitivity of the probes on the DNA microarray. Looking ahead, it may be possible to use the approach developed here to improve the number of SC-b cells formed, as well as alter the differentiation of pancreatic endocrine progenitors to produce all the other endocrine hormone cell types (a, g, d, ε) and reconstruct the proportions found in human islets.
A preparation of monohormonal cells that respond to a single glucose challenge has been previously reported, but those cells were not shown to express the key b cell identity marker NKX6-1 nor function in vivo (Cheng et al., 2012) . Recent work has shown that differentiation protocols that generate higher levels of NKX6-1 lead to better outcomes for the pancreatic progenitor transplants . Conditional knockout studies have shown that NKX6-1 is necessary for b cell function in adult mouse islets, suggesting that coexpression of these factors in SC-b cells may be part of the reason for their functional abilities (Taylor et al., 2013) . Despite the potential malleability of gene expression levels, we consider the key feature of b cells to be their function, i.e., their ability to repeatedly respond to glucose by secreting insulin in a way that can be quantified and observed in vivo and in vitro. The characterization of SC-b cell physiology can be extended in future studies by performing a time course of insulin synthesis and secretion and determining how long these cells maintain this phenotype in vitro and in vivo.
We note that the insulin detected in serum of transplanted SC-b cells was generally lower than that of animals transplanted with cadaveric donor islets on a per cell basis (Tables S2 and S3 ). One possibility is that the other cell types in islets, mesenchyme, endothelial cells, or other endocrine cell types may help engraftment or the vascularization necessary for glucose and insulin exchange from the mouse vasculature. Another possibility is that the slightly larger size of the SC-b clusters compared to the human islets that we received may influence relative insulin amounts secreted, as it has been observed that smaller islets secrete more insulin per cell than larger islets (Fujita et al., 2011) . Nonetheless, the fact that transplantation of SC-b cells consistently results in rapid and glucose-responsive insulin production and that these cells function to treat diabetes in a mouse model is encouraging.
The results described here suggest that SC-b cells present an opportunity for cell therapy. Limited supplies of donated cadaveric islets and the very small amount of human b cell replication achieved in vitro have severely limited human b cell supplies to date. This limitation has restricted transplantation options for patients as well as high-throughput drug screening and disease modeling. A single 68 kg (150 lb) patient requires roughly 340-750 million transplanted islet cells to effectively resolve type 1 diabetes via islet transplantation (McCall and Shapiro, 2012; Shapiro et al., 2006) . The strategy that we describe here may address this limitation, as it utilizes a renewable cell source and a scalable method, with cells grown 300 million at a time in suspension in a single 500 ml flask. Thus, one or two flasks may be sufficient for treatment of a patient. An additional clinical advantage of SC-b cells compared to previously proposed therapies using pancreatic progenitors is that these cells do not require an extended posttransplantation period before observing insulin production. Immediate insulin production makes it theoretically possible to reduce patient exogenous insulin requirements from the first few days posttransplantation.
These cells also present new opportunities for b cell studies. A single flask could provide enough cells for screening 30,000 compounds in a 384-well format seeded with 10,000 cells per well. Unlike primary human b cells, SC-b cells can also be generated from pluripotent cells of any desired genetic background. hiPSC, which function like hESC, can be generated from any fibroblasts or other somatic cell types through introduction of a small set of pluripotency genes (Takahashi and Yamanaka, 2006) . hiPSC cells from patients with diabetes or other metabolic syndromes have been derived. Work in progress in our laboratory has demonstrated that this protocol can be applied to differentiate SC-b cells from diabetic hiPSC lines, which could be used for disease modeling and the study of b cell function or susceptibility to stress or immune attack. Furthermore, technologies like TALEN and CRISPR enable genome editing of hESC or hiPSC cells to test variants identified by genome-wide association studies (GWAS). SC-b cell drug responses could be compared between genetically matched pairs of mutant and nonmutant b cells (Ding et al., 2013) . Identification and testing of novel biomarkers for b cell function or pharmacogenetics is also enabled by the combination of these technologies. Thus SC-b cells provide a new platform for in vitro drug discovery and characterization for human metabolism and diabetes.
The generation of SC-b cells provides a potentially useful step toward the generation of islets and pancreatic organs. Incorporating pancreatic niche cells, such as mesenchymal or endothelial cells, into cultures of stem-cell-derived pancreatic cells may be beneficial (Sneddon et al., 2012; Lammert et al., 2001) . Other evidence suggests that the presence of a and g cells may be important for precise tuning of normal b cell function (Rodriguez-Diaz et al., 2011) . Tissue engineering of a pancreatic organ will require incorporation of exocrine and ductal tissue, possibly in a specified architecture. Much work remains to be done to achieve any of these therapeutic, disease modeling, drug discovery, or tissue engineering goals, but the generation of SC-b cells represents a step toward making a clinical impact with stem cell biology.
EXPERIMENTAL PROCEDURES
Cell Culture Undifferentiated hPSC lines were maintained in mTeSR1 (StemCell Technologies) in 500 ml spinner flasks (Corning, VWR) placed on a 9-Position stir plate (Chemglass) set at rotation rate of 70 rpm in a 37 C incubator, 5% CO 2 , and 100% humidity. The human embryonic stem cell line HUES8 and two hiPSC cell lines (hiPSC-1 and hiPSC-2) were utilized for all experiments shown. HUES8 cells are part of the NIH human embryonic stem cell registry eligible for NIH funding and differentiate well into multiple lineages (Chetty et al., 2013) . Using significant modifications of previously published protocols (Schulz et al., 2012; Rezania et al., 2012; Hrvatin et al., 2014) , populations of DE, PGT, and PP1 cells were generated as described below. For initiation of SCb cell differentiation, HUES8, hiPSC-1, or hiPSC-2 cells were seeded at 6 3 10 5 cells/ml in mTeSR1 media+10mM Y27632. The differentiation was started 48 hr later for HUES8 and 72 hr later for hiPSC-1 and hiPSC-2 by changing media to Day media. Media changes were as follows. Day 1: S1 + 100 ng/ml ActivinA (R&D Systems) + 3 mM Chir99021 (Stemgent). Day 2: S1 + 100 ng/ml ActivinA. Days 4, 6: S2 + 50 ng/ml KGF (Peprotech). Days 7, 8: S3 + 50 ng/ml KGF + 0.25 mM Sant1 (Sigma) + 2 mM RA (Sigma) + 200 nM LDN193189 (only Day 7) (Sigma) + 500 nM PdBU (EMD Millipore). Days 9, 11, 13: S3 + 50 ng/ml KGF + 0.25 mM Sant1 + 100 nM RA. Days 14, 16: S5 + 0.25 mM Sant1 + 100 nM RA + 1 mM XXI (EMD Millipore) + 10 mM Alk5i II (Axxora) + 1 mM T3 (EMD Millipore) + 20 ng/ml Betacellulin (Thermo Fisher Scientific). Days 18, 20: S5 + 25 nM RA + 1 mM XXI + 10 mM Alk5i II + 1 mM T3 + 20 ng/ ml Betacellulin. Days 21-35 (change every second day): S6 + 10 mM Alk5i II + 1 mM T3. In the final stage, cells were analyzed between 28 and 33 days of the protocol. For generation of PH protocol cells, HUES8 was used, and the same differentiation protocol was followed until day 14. On days 14 and 16, cells were fed with S3 + 1 mM Alk5i II, 200 nM LDN193189, and 100 nM RA . On day 18 and onward, cells were fed every other day with S3 + 100 nM RA. Cells were maintained in this media until experimental analysis. Cells were maintained in culture and tested after the same number of days in differentiation media as the SC-b cells to control for the impact of time in culture.
Glucose-Stimulated Insulin Secretion
Human islets (500 IEQ, Prodo Laboratories) or differentiated PH or SC-b cells (5 3 10 5 cells between 28 and 35 days of differentiation) were sampled. Clusters were washed with Krebs (Krb) buffer and were then preincubated in low (2 mM) glucose Krb for 2 hr to remove residual insulin. Clusters were washed two times in Krb, incubated in low-glucose Krb for 30 min, and supernatant collected. Then clusters were washed two times in Krb, incubated in high glucose Krb for 30 min, and supernatant collected. This sequence was repeated two additional times. Finally, clusters were incubated in Krb containing 2 mM glucose and 30 mM KCl (depolarization challenge) for 30 min and then supernatant collected. Clusters were then dispersed into single cells using TrypLE Express (Life Technologies), and cell number was counted automatically by a Vi-Cell (Beckman Coulter). Supernatant samples containing secreted insulin were processed using the Human Ultrasensitive Insulin ELISA (ALPCO Diagnostics).
Proinsulin and Insulin Content Measurements
Acid-ethanol extraction was used to extract protein, and proinsulin and insulin contact was measured using intact human proinsulin (BioVendor) and human Ultrasensitive Insulin ELISA kits.
Calcium Imaging
Clusters were attached to plates coated with hESC-qualified Matrigel (BD Biosciences). After incubation and attachment, the wells were washed with Krb buffer, incubated with Fluo4-AM (Life Technologies) for 45 min, washed with Krb buffer, and then incubated further in 37 C incubator for an additional 15 min without the dye. Clusters were then immediately staged on an AxioZoom V16 microscope (Carl Zeiss) for acquisition of high-resolution time series imaging. Time series images were acquired at single-cell resolution of 803 magnification, every 17 s. Progression of glucose challenges and time of the stimulation during imaging was as follows: 5 min in low (2 mM) glucose Krb, wash, 5 min high (20 mM) glucose Krb, and wash. This sequential treatment was repeated two more times, and then a final 5 min incubation 2 mM glucose Krb containing 30 mM KCl was performed. Images were analyzed using ImageJ /Fiji. Analysis of the cluster was done by the measurement of the average fluorescence intensity of the whole cluster (population analysis) or average fluorescence intensity of the individual cells within the cluster (single cell analysis).
Immunohistochemistry
Differentiated cell clusters or islets were fixed with 4% PFA for 1 hr at room temperature (RT), washed, embedded in Histogel (Thermo), and sectioned for histological analysis. Before staining, paraffin was removed from sections using Histoclear (Thermoscientific), rehydrated, and underwent antigen retrieval by treatment with 0.1M EDTA (Ambion) in pressure cooker (Proteogenix) for 2 hr. For staining, slides were blocked with PBS+0.1% Triton X-100 (VWR)+5% donkey serum (Jackson Immunoresearch) for 1 hr at RT, incubated with primary antibodies overnight at 4 C, washed, incubated with secondary antibody incubation for 2 hr at RT, and washed. For imaging, samples were mounted in Vectashield (Vector Laboratories), covered with coverslips, and sealed with nail polish. Representative images were taken using an Olympus IX51 Microscope or Zeiss LSM 510 or 710 confocal microscope.
Flow Cytometry
Differentiated cell clusters or islets were dispersed into single-cell suspension by incubation in TrypLE Express at 37 C, fixed with 4% PFA on ice for 30 min, washed once in PBS, and incubated in blocking buffer (PBS+0.1% Triton X-100+5% donkey serum) on ice for 1 hr. Cells were then resuspended in blocking buffer with primary antibodies and incubated at 4 C overnight. Cells were washed twice in blocking buffer and were then incubated in blocking buffer with secondary antibodies on ice for 2 hr. Cells were then washed thrice and analyzed using the LSR-II flow cytometer (BD Biosciences). Analysis of the results was performed using FlowJo software.
Gene Expression Analysis of Sorted Cells
To analyze global gene expression of SC-b cells, we used a recently described fixation and sorting strategy to isolate NKX6-1+/INS+ SC-b cells from the heterogenous cell clusters (Hrvatin et al., 2014) . In brief, dispersed and fixed cells were incubated with primary antibodies for 30 min in buffer containing RNasin, washed twice, and then incubated with secondary antibodies in buffer containing RNasin for 30 min each. After antibody staining, cells were sorted by fluorescence-activated cell sorting. RNA was extracted with the RecoverAll Total Nucleic Acid Isolation Kit (Ambion). The Illumina TotalPrep RNA Amplification Kit (Life Technologies) was used to make cRNA, which was run on Human HT-12 Expression BeadChips (Illumina) using the Whole-Genome Expression Direct Hybridization kit (Illumina). Chips were scanned on the Illumina Beadstation 500. These SC-b cell microarray data and the previously published hPSC, PH, fetal b, and adult b cell data (Hrvatin et al., 2014) were imported into the R statistical computing platform using the programming packages lumi and EMA. Samples were analyzed by hierarchical clustering using Pearson's correlation and Ward linkage. The pattern of clustering was robust to other distance and linkage metrics.
Electron Microscopy
To analyze granular ultrastructure, cadaveric pancreatic islets or differentiated hPSC were fixed at RT for 2 hr with a mixture containing 1.25% PFA, 2.5% glutaraldehyde, and 0.03% picric acid in 0.1 M sodium cocodylate buffer (pH 7.4). Samples were then washed in 0.1 M cacodylate buffer and postfixed at RT with a mixture of 1% OsO4/1.5% KFeCN6 once for 2 hr then once for 1 hr. After washing with water, samples were stained in 1% aqueous uranyl acetate for 1 hr, washed, and subsequently dehydrated. A 1 hr incubation in propyleneoxide was followed by infiltration overnight in At select times, mice were analyzed by performing a glucose challenge, measuring blood glucose, and collecting serum to measure human insulin. After fasting the mice for 16 hr overnight, mice were injected intraperitoneal (IP) with 2 g D-(+)-glucose/1 kg body weight and blood glucose measured and serum collected at 0 and 30 min post glucose injection. Serum human insulin levels were quantified using the Human Ultrasensitive Insulin ELISA. Kidneys containing the grafts were dissected from the mice, fixed in 4% PFA overnight, embedded in paraffin, and sectioned for histological analysis. IHC analysis was performed as described above. All experiments were in accordance with the guidelines of the appropriate committee.
Statistical Analysis
Statistical analysis was performed by using unpaired and paired t tests. Box and whisker plots were generated with BoxPlorR (http://boxplot.tyerslab. com/) using default settings for box and whisker length.
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